A Kyiv clinic, founded in 1994 and formerly trading as EmCell, that treats patients with fetal stem cell transplantation across a wide range of chronic conditions.
The Unique Cell Treatment Clinic is a private cell therapy clinic in Kyiv, Ukraine. Its site traces its history to 1993 and 1994, when a cell therapy clinic was founded at the National Medical University in Kyiv by Professor Alexander Smikodub, and states that the organisation traded under the EmCell name until June 2011, when it was restructured under its present name.
The clinic is now directed by Alexander Smikodub Jr., MD PhD, the founder's son. The site says the clinic has treated thousands of patients from around the world and performed about ten thousand transplantations; these are the clinic's own figures and are not verified here.
The treatment the site describes is transplantation of fetal stem cells, which it characterises as unspecialised cells with a large capacity for growth and differentiation that retain pluripotent properties and can develop along mesenchymal, ectodermal and endodermal lines. The site does not set out in detail how this material is obtained or under what regulatory framework, which readers should note and ask about directly. Fetal cell therapy is not an accepted treatment in most countries and carries ethical and safety questions that the site does not address on the pages read.
The site lists more than twenty-five conditions it says it treats, among them amyotrophic lateral sclerosis, Alzheimer's disease, autism, cancer, cerebral palsy, diabetes, heart disease, hearing loss, HIV and AIDS, multiple sclerosis, Parkinson's disease, muscular dystrophy, ulcerative colitis and the after-effects of COVID-19. That range is exceptionally broad and no evidence of effectiveness is offered on the pages read. The site publishes no street address, no prices and no accreditation.
The site lists more than twenty-five conditions; those below are the ones it names explicitly on the pages read.
The site says the clinic treats by transplanting fetal stem cells, which it describes as unspecialised and pluripotent.
The site names the founder and the current director; no other clinical staff are identified.
The site gives a postal address of Ukraine, Kiev 03110, P.O. Box 8, and a mobile telephone number, but publishes no street address, no opening hours and no description of the premises or laboratory. It lists regional representatives, including a contact for the Arab world and a partner company covering China and Taiwan, and offers the site in English, Chinese, Italian, German, Russian and Arabic. No accreditation is stated.
The site does not publish prices; costs are discussed only after a case is submitted for assessment.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.